Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Home Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

/ Publications

Share the Post

About the Author

AadiSite Support

Related Posts

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines
Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
Read More
Loretta Itri, MD

Comments

Comments are closed.